Skip to main content

Irbesartan (Monograph)

Brand name: Avapro
Drug class: Angiotensin II Receptor Antagonists
VA class: CV805
Chemical name: 2-Butyl-3-[[2′(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
Molecular formula: C25H28N6O3S•½C4H4 O4
CAS number: 138402-11-6

Medically reviewed by Drugs.com on Oct 28, 2024. Written by ASHP.

Warning

  • May cause fetal and neonatal morbidity and mortality if used during pregnancy.1 26 71 72 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • If pregnancy is detected, discontinue as soon as possible.1 26 72

Introduction

Angiotensin II receptor (AT1) antagonist (i.e., angiotensin II receptor blocker, ARB).1 2 4 5 6 21 22 23

Uses for Irbesartan

Hypertension

Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 2 3 4 5 6 14 15 16 17 18 21 22 23 1200

Angiotensin II receptor antagonists are recommended as one of several preferred agents for the initial management of hypertension according to current evidence-based hypertension guidelines; other options include ACE inhibitors, calcium-channel blockers, and thiazide diuretics.501 502 503 504 1200 While there may be individual differences with respect to recommendations for initial drug selection and use in specific patient populations, current evidence indicates that these antihypertensive drug classes all generally produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.501 502 503 504 1200 1213

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201

A 2017 ACC/AHA multidisciplinary hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)

Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200

Category

SBP (mm Hg)

DBP (mm Hg)

Normal

<120

and

<80

Elevated

120–129

and

<80

Hypertension, Stage 1

130–139

or

80–89

Hypertension, Stage 2

≥140

or

≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210

Previous hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients501 504 536 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the current ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient’s BP treatment goal.1200 1220 1229

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment recommended by ACC/AHA for all adults with hypertension.1200

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.1200

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to angiotensin II receptor antagonists.501 504 1200 However, the combination of an ACE inhibitor or an angiotensin II receptor antagonist with a calcium-channel blocker or thiazide diuretic produces similar BP lowering in black patients as in other racial groups.1200

Angiotensin II receptor antagonists or ACE inhibitors may be particularly useful in hypertensive patients with diabetes mellitus or CKD; angiotensin II receptor antagonists also may be preferred, as an alternative to ACE inhibitors, in hypertensive patients with heart failure or ischemic heart disease and/or post-MI.501 502 504 523 524 527 534 535 536 543 1214 1215

Diabetic Nephropathy

Management of diabetic nephropathy manifested by elevated Scr and proteinuria (urinary protein excretion >300 mg daily) in patients with type 2 diabetes mellitus and hypertension.1

A recommended agent in the management of patients with diabetes mellitus and persistent albuminuria who have modestly elevated (30–300 mg/24 hours) or higher (>300 mg/24 hours) levels of urinary albumin excretion; slows rate of progression of renal disease in such patients.49 51 52 53 535 536 1232

Heart Failure

Angiotensin II receptor antagonists have been used in the management of heart failure† [off-label].524 528 800

Because of their established benefits, ACE inhibitors have been the preferred drugs for inhibition of the renin-angiotensin-aldosterone (RAA) system in patients with heart failure and reduced left ventricular ejection fraction (LVEF); 524 however, some evidence indicates that therapy with an ACE inhibitor (enalapril) may be less effective than angiotensin receptor-neprilysin inhibitor (ARNI) therapy (e.g., sacubitril/valsartan) in reducing cardiovascular death and heart failure-related hospitalization.701 702 703 800

Angiotensin II receptor antagonists may be used as an alternative for those patients in whom an ACE inhibitor or ARNI is inappropriate.524 800

ACCF, AHA, and the Heart Failure Society of America (HFSA) recommend that patients with chronic symptomatic heart failure and reduced LVEF (NYHA class II or III) who are able to tolerate an ACE inhibitor or angiotensin II receptor antagonist be switched to therapy containing an ARNI to further reduce morbidity and mortality.800

Irbesartan Dosage and Administration

General

BP Monitoring and Treatment Goals

Administration

Oral Administration

Administer orally once daily without regard to meals.1 21

Dosage

Pediatric Patients

Hypertension
Oral

Children 6–12 years of age: Initially, 75 mg once daily recommended by experts; dosage may be increased every 2–4 weeks until BP controlled, maximum dosage reached (150 mg once daily), or adverse effects occur.1150

Children ≥13 years of age: Initially, 150 mg once daily recommended by experts; dosage may be increased every 2–4 weeks until BP controlled, maximum dosage reached (300 mg once daily), or adverse effects occur.1150

Adults

Hypertension
Irbesartan Therapy
Oral

Manufacturer recommends initial dosage of 150 mg once daily in adults without intravascular volume depletion.1 In adults with depletion of intravascular volume, the usual initial dosage is 75 mg once daily.1 24

Usual dosage: 150–300 mg once daily;1 1200 no additional therapeutic benefit with higher dosages or with twice-daily dosing.1

Irbesartan/Hydrochlorothiazide Fixed-combination Therapy
Oral

Manufacturer states fixed-combination preparation can be used for initial treatment of hypertension in patients who are likely to need multiple drugs to achieve their BP goals.26 Consider potential benefits and risks of initiating therapy with the fixed combination.26

If BP is not adequately controlled by monotherapy with irbesartan or hydrochlorothiazide, can switch to fixed-combination tablets (irbesartan 150 mg and 12.5 mg hydrochlorothiazide; then irbesartan 300 mg and hydrochlorothiazide 12.5 mg), administered once daily.26 Can increase dosage to irbesartan 300 mg and hydrochlorothiazide 25 mg daily, if needed, to control BP.26

In patients receiving fixed-combination tablets as initial therapy, the usual starting dosage is irbesartan 150 mg and hydrochlorothiazide 12.5 mg once daily.26 May increase dosage after 1–2 weeks of therapy to a maximum of irbesartan 300 mg and hydrochlorothiazide 25 mg once daily.26

Diabetic Nephropathy
Oral

Initial dosage of 75 mg once daily used in clinical trial.1 Increase dosage to target maintenance dosage of 300 mg once daily.1 No data available on effects of lower dosages.1

Special Populations

Hepatic Impairment

No initial dosage adjustments necessary.1 26

Renal Impairment

No initial dosage adjustments necessary.1 26

Irbesartan/hydrochlorothiazide fixed combination not recommended in patients with severe renal impairment.26

Geriatric Patients

No initial dosage adjustments necessary.1 26

Volume- and/or Salt-depleted Patients

Correct volume and/or salt depletion prior to initiation of therapy or initiate therapy using lower initial dosage (75 mg once daily).1 24 26 Fixed-combination tablets containing irbesartan and hydrochlorothiazide are not recommended as initial therapy in patients with intravascular volume depletion.26

Detailed Irbesartan dosage information

Cautions for Irbesartan

Contraindications

Warnings/Precautions

Warnings

Fetal/Neonatal Morbidity and Mortality

Possible reduction in fetal renal function and increase in fetal and neonatal morbidity and mortality when drugs that act on the renin-angiotensin system (e.g., angiotensin II receptor antagonists, ACE inhibitors) are used during the second and third trimesters of pregnancy.1 26 (See Boxed Warning.) Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.1 26 Potential neonatal effects include skull hypoplasia, anuria, hypotension, renal failure, and death.1 26

Discontinue irbesartan as soon as possible when pregnancy is detected, unless continued use is considered lifesaving.1 72 Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy.13

Sensitivity Reactions

Anaphylactoid reactions and/or angioedema possible;1 26 not recommended in patients with a history of angioedema associated with or unrelated to ACE inhibitor or angiotensin II receptor antagonist therapy.544 545 73

Other Warnings and Precautions

Hypotension

Possible symptomatic hypotension, particularly in volume- and/or salt-depleted patients (e.g., those receiving diuretics or undergoing dialysis).1 26 (See Volume- and/or Salt-depleted Patients under Dosage and Administration.)

Transient hypotension is not a contraindication to additional doses; may reinstate therapy cautiously after BP is stabilized (e.g., with volume expansion).1 26

Malignancies

In July 2010, FDA initiated a safety review of angiotensin II receptor antagonists after a published meta-analysis found a modest but statistically significant increase in risk of new cancer occurrence in patients receiving an angiotensin II receptor antagonist compared with control.120 121 123 126 However, subsequent studies, including a larger meta-analysis conducted by FDA, have not shown such risk.126 127 128 129 Based on currently available data, FDA has concluded that angiotensin II receptor antagonists do not increase the risk of cancer.126

Renal Effects

Possible oliguria, progressive azotemia, and, rarely, acute renal failure and/or death in patients with severe heart failure.1 26

Increases in BUN and Scr possible in patients with renal artery stenosis, CKD, or volume depletion.1 26

Use of Fixed Combinations

When used in fixed combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with hydrochlorothiazide.26

Specific Populations

Pregnancy

Category D.1 26 (See Boxed Warning.)

May cause fetal and neonatal morbidity and mortality when administered to a pregnant woman.1 26 Discontinue as soon as possible when pregnancy is detected.1 26 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

Lactation

Distributed into milk in rats; not known whether distributed into human milk.1 26 Discontinue nursing or the drug.1 26

Pediatric Use

If oliguria or hypotension occurs in neonates with a history of in utero exposure to irbesartan, support BP and renal function; exchange transfusions or dialysis may be required.1 26 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

Dosages of up to 4.5 mg/kg once daily did not appear to effectively lower BP in pediatric patients 6–16 years of age.1 Not studied in children <6 years of age.1

Safety and efficacy of the fixed-combination preparation containing irbesartan and hydrochlorothiazide not established.26

Geriatric Use

No substantial differences in safety or efficacy of irbesartan monotherapy or fixed-combination containing irbesartan and hydrochlorothiazide relative to younger adults, but increased sensitivity cannot be ruled out.1 26

Renal Impairment

Use with caution.1

Deterioration of renal function may occur.1 26 (See Renal Effects under Cautions.)

Use of irbesartan in fixed combination with hydrochlorothiazide is not recommended in patients with severe renal impairment.26

Black Patients

BP reduction may be smaller in black patients than in patients of other races.1 26 69 70 1200 (See Hypertension under Uses.)

Common Adverse Effects

Diarrhea, dyspepsia/heartburn, fatigue in patients with hypertension; also, dizziness, orthostatic dizziness, and orthostatic hypotension in patients with diabetic nephropathy.1

Drug Interactions

Metabolized principally by CYP2C9.1 26 Does not substantially induce or inhibit CYP1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.1 26

Drugs Affecting Hepatic Microsomal Enzymes

Potential pharmacokinetic interaction (decreased irbesartan metabolism) with CYP2C9 inhibitors.1 26

Specific Drugs

Drug

Interaction

Comments

ACE Inhibitors

Increased risk of renal impairment, hyperkalemia, and hypotension1 26

Generally avoid concomitant use1 26

Monitor BP, renal function, and electrolytes if used concomitantly1 26

Aliskiren

Increased risk of renal impairment, hyperkalemia, and hypotension1 26 550

Generally avoid concomitant use1 26

Monitor BP, renal function, and electrolytes if used concomitantly1 26 550

Concomitant use contraindicated in patients with diabetes mellitus1 26 550

Avoid concomitant use in patients with GFR<60 mL/minute1 26 550

Angiotensin II receptor antagonists

Increased risk of renal impairment, hyperkalemia, and hypotension1 26

Generally avoid concomitant use1 26

Monitor BP, renal function, and electrolytes if used concomitantly1 26

Digoxin

Pharmacologic and/or pharmacokinetic interactions unlikely1 26

Diuretics, potassium-sparing

Possible hyperkalemia1 26

Monitor serum potassium concentrations1 26

Hydrochlorothiazide

Pharmacokinetic interactions unlikely1 26

Additive hypotensive effects1 26

Lithium

Elevations in lithium concentrations and lithium toxicity reported1 26

Carefully monitor serum lithium concentrations 1 26 `

Nifedipine

Decreased irbesartan metabolism in vitro; alteration of irbesartan pharmacokinetics not observed in vivo1 26

NSAIAs, including selective cyclooxygenase-2 (COX-2) inhibitors

Possible deterioration of renal function in geriatric, volume-depleted, or renally impaired patients1 26

Possible reduced antihypertensive effects1

Monitor renal function periodically1

Salt substitutes, potassium-containing

Possible hyperkalemia1 26

Monitor serum potassium concentrations1 26

Tolbutamide

Possible decreased irbesartan metabolism26

Warfarin

Pharmacologic and/or pharmacokinetic interaction unlikely1 26
Irbesartan drug interactions (more detail)

Irbesartan Pharmacokinetics

Absorption

Bioavailability

Peak plasma concentration generally achieved 1.5–2 hours after oral dose.1 Absolute bioavailability is about 60–80%.1 26

Onset

Antihypertensive effect evident within 2 weeks, with maximum BP reduction after 2–4 weeks.1 26

Food

Food does not affect bioavailability.1 26

Distribution

Extent

Crosses the placenta and is distributed in the fetus in animals.1 26

Crosses the blood-brain barrier poorly, if at all, in animals.1 15

Distributed into milk in rats; not known whether distributed into human milk.1 26

Plasma Protein Binding

90% (principally albumin and α1-acid glycoprotein).1 26

Elimination

Metabolism

Undergoes hepatic metabolism by glucuronide conjugation and oxidation (principally by CYP2C9) to inactive metabolites.1 26

Elimination Route

Eliminated in urine and feces (via bile).1 26

Half-life

Terminal elimination half-life: 11–15 hours.1

Special Populations

Not removed by hemodialysis.1 26 Pharmacokinetics not substantially altered by hemodialysis or renal impairment.1 26

Stability

Storage

Oral

Tablets

15–30°C.1 26

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Irbesartan

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

75 mg

Avapro

Sanofi-Aventis

150 mg

Avapro

Sanofi-Aventis

300 mg

Avapro

Sanofi-Aventis
Irbesartan Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

150 mg with Hydrochlorothiazide 12.5 mg

Avalide

Sanofi-Aventis

300 mg with Hydrochlorothiazide 12.5 mg

Avalide

Sanofi-Aventis

AHFS DI Essentials™. © Copyright 2025, Selected Revisions November 5, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Sanofi-Aventis. Avapro (irbesartan) tablets prescribing information. Bridgewater, NJ; 2016 Jul.

2. van den Meiracker AH, Admiraal PJJ, Janssen JA et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension. 1995; 25:22-9. https://pubmed.ncbi.nlm.nih.gov/7843749

3. Ellis ML, Patterson JH. A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacotherapy. 1996; 16:849-60. https://pubmed.ncbi.nlm.nih.gov/8888079

4. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med. 1995; 155:1361-8. https://pubmed.ncbi.nlm.nih.gov/7794084

5. Burnier M, Buclin T, Biollaz J et al. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. Kidney Int. 1996; 49(Suppl 55):S-24–S-29.

6. Velasquez MT. Angiotensin II receptor blockers: a new class of hypertensive drugs. Arch Fam Med. 1996; 5:351-356. https://pubmed.ncbi.nlm.nih.gov/8640326

7. Anon. Valsartan for hypertension. Med Lett Drugs Ther. 1997; 39:43-4. https://pubmed.ncbi.nlm.nih.gov/9137296

8. Pitt B, Segal R, Martinez FA et al for the ELITE study investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997; 349:747-52. https://pubmed.ncbi.nlm.nih.gov/9074572

10. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1995; 37:45-50. https://pubmed.ncbi.nlm.nih.gov/7760767

13. US Food and Drug Administration. Dangers of ACE inhibitors during second and third trimesters of pregnancy. FDA Med Bull. 1992; 22:2.

14. Pool JL, Guthrie RM, Littlejohn T et al. The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1996; 9:152A.

15. Fogari R, Zanchetti A, Moran S et al et al. Once-daily irbesartan provides full 24-hour ambulatory blood pressure control. J Hypertens. 1997; 15(Suppl 4):S113.

16. Stumpe KO, Haworth D, Höglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and atenolol for the treatment of hypertension. J Hypertens. 1997; 15(Suppl 4):S115.

17. Larochelle P, Flack JM, Hannah S et al et al. Irbesartan versus enalapril in severe hypertension. Am J Hypertens. 1997; 10:131A.

18. Mimran A, Ruilope L, Kerwin L et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of hypertension. J Hypertens. 1997; 15(Suppl 4):S117.

19. Cazaubon C, Gougat J, Bousquet F et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993; 265: 826-34. https://pubmed.ncbi.nlm.nih.gov/8496828

21. Anon. Irbesartan for hypertension. Med Lett Drugs Ther. 1998; 40:18-9. https://pubmed.ncbi.nlm.nih.gov/9465857

22. Kossler-Taub K, Littlejohn T, Elliott W et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998; 11:445-53. https://pubmed.ncbi.nlm.nih.gov/9607383

23. Larochelle P, Flack JM, Marbury TC et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol. 1997; 80:1613-5. https://pubmed.ncbi.nlm.nih.gov/9416950

24. Bristol-Myers Squibb Company. Princeton, NJ: Personal communication.

25. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9-38A.

26. Sanofi-aventis. Avalide (irbesartan-hydrochlorothiazide) tablets prescribing information. Bridgewater, NJ; 2016 Feb.

27. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. https://pubmed.ncbi.nlm.nih.gov/10818056

28. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. https://pubmed.ncbi.nlm.nih.gov/10818055

29. Merck & Co, Inc. Results of second heart-failure study with Cozaar presented at American Heart Association scientific sessions. West Point, PA; 1999 Nov 10. Press release from Yahoo web site. http://news.yahoo.com

30. Food and Drug Administration. Avapro (irbesartan) and Avalide (irbesartan/hydrochlorothiazide) tablets [May 9, 2000: Bristol-Myers Squibb]. MedWatch drug labeling changes. Rockville, MD; May 2000. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm172834.htm

31. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. https://pubmed.ncbi.nlm.nih.gov/10977801

32. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62. https://pubmed.ncbi.nlm.nih.gov/9635947

33. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997; 349:747-52. https://pubmed.ncbi.nlm.nih.gov/9074572

38. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001. From ACC website. Accessed July 25, 2002. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx

40. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345:1667-75. https://pubmed.ncbi.nlm.nih.gov/11759645

41. Novartis. Diovan (valsartan) tablets prescribing information. East Hanover, NJ; 2002 Jul.

42. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: a statement for health professional from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002; 106:143-60. https://pubmed.ncbi.nlm.nih.gov/12093785

43. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345:851-60. https://pubmed.ncbi.nlm.nih.gov/11565517

44. Blankfield RP. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med. 2002: 346;705. Letter.

45. Lewis EJ. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med. 2002: 346;706. Letter.

46. Williams MA, Fleg JL, Ades PA et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥ 75 years of age). An American Heart Association Scientific Statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac rehabilitation, and Prevention. Circulation. 2002; 105:1735-43. https://pubmed.ncbi.nlm.nih.gov/11940556

47. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861-9. https://pubmed.ncbi.nlm.nih.gov/11565518

48. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345:870-6. https://pubmed.ncbi.nlm.nih.gov/11565519

49. Remuzzi G. Slowing the progression of diabetic nephropathy. N Engl J Med. 1993; 329:1496-7. https://pubmed.ncbi.nlm.nih.gov/8413463

51. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. https://pubmed.ncbi.nlm.nih.gov/8622249

52. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994; 271:275-9. https://pubmed.ncbi.nlm.nih.gov/8295285

53. Fournier A. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1994; 330:937. https://pubmed.ncbi.nlm.nih.gov/8114873

54. Kasiske VL, Kalil RSN, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993; 118:129-138. https://pubmed.ncbi.nlm.nih.gov/8416309

55. Björck S, Mulec H, Johnsen SA et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992; 304:339-43. https://pubmed.ncbi.nlm.nih.gov/1540729

56. Cook J, Daneman D, Spino M et al. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr. 1990; 117:39-45. https://pubmed.ncbi.nlm.nih.gov/2196359

57. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329:1456-62. https://pubmed.ncbi.nlm.nih.gov/8413456

58. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. https://pubmed.ncbi.nlm.nih.gov/12479770

59. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. https://pubmed.ncbi.nlm.nih.gov/12479763

66. Morgensen CE, Neldman S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321:1440-4. https://pubmed.ncbi.nlm.nih.gov/11110735

67. Frohlich ED. Treating hypertension—what are we to believe? N Engl J Med. 2003; 348:639-401.

69. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. https://pubmed.ncbi.nlm.nih.gov/15811979

70. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. https://pubmed.ncbi.nlm.nih.gov/15811986

71. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354:2443-51. https://pubmed.ncbi.nlm.nih.gov/16760444

72. Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. 2006 June 7. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053113.htm

73. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf. 2002; 25:73-6.

120. Food and Drug Administration. FDA drug safety communication: ongoing safety review of the angiotensin receptor blockers and cancer. Rockville, MD; 2010 Jul 15. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218845.htm

121. Sipahi I, Debanne SM, Rowland DY et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11:627-36. https://pubmed.ncbi.nlm.nih.gov/20542468

122. Nissen SE. Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncol. 2010; 11:605-6. https://pubmed.ncbi.nlm.nih.gov/20542469

123. Sica DA. Angiotensin receptor blockers and the risk of malignancy: a note of caution. Drug Saf. 2010; 33:709-12. https://pubmed.ncbi.nlm.nih.gov/20701404

126. Food and Drug Administration. FDA drug safety communication: No increase in risk of cancer with certain blood pressure drugs-angiotensin receptor blockers (ARBs). Rockville, MD; 2011 Jun 2. Available from FDA website. Accessed 2011 Jun 15. http://www.fda.gov/Drugs/DrugSafety/ucm257516.htm

127. Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011; 12:65-82. https://pubmed.ncbi.nlm.nih.gov/21123111

128. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011; 29:623-35. https://pubmed.ncbi.nlm.nih.gov/21358417

129. Pasternak B, Svanström H, Callréus T et al. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011; 123:1729-36. https://pubmed.ncbi.nlm.nih.gov/21482967

130. Volpe M, Morganti A. 2010 Position Paper of the Italian Society of Hypertension (SIIA): Angiotensin Receptor Blockers and Risk of Cancer. High Blood Press Cardiovasc Prev. 2011; 18:37-40. https://pubmed.ncbi.nlm.nih.gov/21612311

131. Siragy HM. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag. 2011; 7:297-313. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104607/ https://pubmed.ncbi.nlm.nih.gov/21633727

132. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362:772-6. https://pubmed.ncbi.nlm.nih.gov/13678870

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. https://pubmed.ncbi.nlm.nih.gov/24352797

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. https://pubmed.ncbi.nlm.nih.gov/23817082

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. https://pubmed.ncbi.nlm.nih.gov/24243703

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. https://pubmed.ncbi.nlm.nih.gov/24341872

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. https://pubmed.ncbi.nlm.nih.gov/24424788

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. https://pubmed.ncbi.nlm.nih.gov/24549531

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. https://pubmed.ncbi.nlm.nih.gov/24352710

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. https://pubmed.ncbi.nlm.nih.gov/24352759

511. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31:2115-27. https://pubmed.ncbi.nlm.nih.gov/19139601

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. https://pubmed.ncbi.nlm.nih.gov/24591473

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471. https://pubmed.ncbi.nlm.nih.gov/23166211

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327. https://pubmed.ncbi.nlm.nih.gov/23741058

525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458-73. https://pubmed.ncbi.nlm.nih.gov/22052934

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. https://pubmed.ncbi.nlm.nih.gov/24788967

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. https://pubmed.ncbi.nlm.nih.gov/23247304

528. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362:759-66. https://pubmed.ncbi.nlm.nih.gov/13678868

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. https://pubmed.ncbi.nlm.nih.gov/24641124

534. Qaseem A, Hopkins RH, Sweet DE et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159:835-47. https://pubmed.ncbi.nlm.nih.gov/24145991

535. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62:201-13. https://pubmed.ncbi.nlm.nih.gov/23684145

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Inter. 2012: 2(suppl): 337-414.

541. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33:1635-701. https://pubmed.ncbi.nlm.nih.gov/22555213

543. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease (2002). From National Kidney Foundation website. http://www.kidney.org/professionals/kdoqi/guidelines_commentaries.cfm

544. Kirk JK. Therapy with angiotensin II receptor antagonists. Clin Geriatrics. From the MultiMedia Health Care website:. http://www.mmhc.com/cg/articles/CG0004/kirk.html

545. Papademetriou V, Reif M, Henry D et al. Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J Clin Hypertens. 2000; 2:372-8.

550. US Food and Drug Administration. FDA Drug Safety Communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). Rockville, MD; 2012 April 20. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm

701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; :. https://pubmed.ncbi.nlm.nih.gov/27206819

702. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993-1004. https://pubmed.ncbi.nlm.nih.gov/25176015

703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther. 2016; 41:119-27. https://pubmed.ncbi.nlm.nih.gov/26992459

800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :. https://pubmed.ncbi.nlm.nih.gov/27208050

1150. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140 https://pubmed.ncbi.nlm.nih.gov/28827377

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. https://pubmed.ncbi.nlm.nih.gov/29133356

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. https://pubmed.ncbi.nlm.nih.gov/29341841

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. https://pubmed.ncbi.nlm.nih.gov/29357392

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. https://pubmed.ncbi.nlm.nih.gov/29447001

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. https://pubmed.ncbi.nlm.nih.gov/28135725

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. https://pubmed.ncbi.nlm.nih.gov/26551272

1213. Reboussin DM, Allen NB, Griswold ME et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71:2176-2198. https://pubmed.ncbi.nlm.nih.gov/29146534

1214. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes 2018. Diabetes Care. 2018; 41:S86-S104. https://pubmed.ncbi.nlm.nih.gov/29222380

1215. de Boer IH, Bangalore S, Benetos A et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40:1273-1284. https://pubmed.ncbi.nlm.nih.gov/28830958

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. https://pubmed.ncbi.nlm.nih.gov/29443671

1218. Messerli FH, Bangalore S, Bavishi C et al. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?. J Am Coll Cardiol. 2018; 71:1474-1482. https://pubmed.ncbi.nlm.nih.gov/29598869

1219. Karmali KN, Lloyd-Jones DM. Global risk assessment to guide blood pressure management in cardiovascular disease prevention. Hypertension. 2017; 69:e2-e9. https://pubmed.ncbi.nlm.nih.gov/28115516

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. https://pubmed.ncbi.nlm.nih.gov/29159416

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. https://pubmed.ncbi.nlm.nih.gov/29710197

1223. LeFevre M. ACC/AHA hypertension guideline: What is new? What do we do?. Am Fam Physician. 2018; 97(6):372-3. https://pubmed.ncbi.nlm.nih.gov/29671534

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. https://pubmed.ncbi.nlm.nih.gov/29242891

1232. American Diabetes Association. 10. Microvascular complications and foot care: standards of medical care in diabetes 2018. Diabetes Care. 2018; 41:S105-S118. https://pubmed.ncbi.nlm.nih.gov/29222381

1233. Remuzzi G, Macia M, Ruggeneti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006; 17(4 Suppl 2 ):S90-7. https://pubmed.ncbi.nlm.nih.gov/16565256

1234. Haller H, Ito S, Izzo JL Jr. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Eng J Med. 2011; 364:907-17. https://pubmed.ncbi.nlm.nih.gov/21388309

Medical Disclaimer